Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP)
inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer …

During the past decade, mass spectrometry imaging (MSI) has become a robust and
versatile methodology to support modern pharmaceutical research and development. The …

Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance
is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical …

Glioblastoma is a malignant brain tumour with a median survival of 14.6 months from
diagnosis. Despite maximal surgical resection and concurrent chemoradiotherapy …

Breast cancer and gynecological tumors seriously endanger women's physical and mental
health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and …

Poly ADP ribose polymerase-1 (PARP-1), one of the most important members of the PARP
protein family, plays a crucial role in DNA damage repair, gene transcription, and apoptosis …

Tumors are spatially heterogeneous tissues that comprise numerous cell types with intricate
structures. By interacting with the microenvironment, tumor cells undergo dynamic changes …

The potential of mass spectrometry imaging (MSI) has been demonstrated in cell and tissue
research since 1970. MSI can reveal the spatial distribution of a wide range of atomic and …

Abstract Pioglitazone is a Peroxisome Proliferator-Activated Receptor (PPAR) agonist of the
thiazolidinedione class of compounds with promising anticancer activity. An innovative …

This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor
activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer …